Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRYREL vs BUPRENORPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
BRYREL (bryrelimab) is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways including PI3K/Akt and MAPK, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cellular cytotoxicity (ADCC).
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Adjuvant treatment of HER2-overexpressing node-positive breast cancer,Metastatic HER2-positive breast cancer (first-line in combination with paclitaxel),Metastatic gastric or gastroesophageal junction adenocarcinoma (HER2-positive, in combination with cisplatin and capecitabine or 5-fluorouracil)
Treatment of opioid dependence (Subutex, Suboxone),Moderate to severe pain (parenteral formulation, e.g., Buprenex),Off-label: Treatment of depression (as adjunctive therapy), chronic pain in opioid-tolerant patients, and neonatal abstinence syndrome (probable).
100 mg orally once daily, with or without food.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
Terminal half-life 6–8 hours in healthy adults; prolonged to 12–15 hours in moderate renal impairment (Cr Cl 30–50 m L/min) and up to 24 hours in severe impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Metabolized by general protein catabolism; no specific metabolic enzymes identified. Elimination via reticuloendothelial system.
Primarily hepatic via N-dealkylation to norbuprenorphine via CYP3A4, with minor contribution from CYP2C8; norbuprenorphine is active and further glucuronidated; undergoes extensive first-pass metabolism; mainly excreted in feces (as unchanged drug and metabolites) and to a lesser extent in urine.
Primarily renal excretion; 70% as unchanged drug via glomerular filtration and tubular secretion; 30% metabolized in liver to inactive metabolites, with 10% biliary excretion.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
45% bound to albumin; minor binding to α1-acid glycoprotein.
Approximately 96% bound to alpha- and beta-globulins, with minimal binding to albumin.
0.8 L/kg (total body water distribution); increased in heart failure (up to 1.2 L/kg) and cirrhosis.
Volume of distribution is 2-4 L/kg (mean ~3.2 L/kg). High Vd indicates extensive tissue distribution, including sequestration in brain and adipose tissue.
Oral: 75% (range 60–85%)
Sublingual: 30-55% (variable due to first-pass metabolism); Oral: ~15% (low due to extensive hepatic metabolism); Transdermal: ~15-20%; Intravenous/Intramuscular: 100%.
GFR 30-59 m L/min: 50 mg once daily; GFR <30 m L/min or on dialysis: 25 mg once daily.
No dosage adjustment required for mild to moderate impairment (GFR >30 m L/min). For severe impairment (GFR <30 m L/min), consider reducing dose and increasing interval; avoid in anuric patients.
Child-Pugh class A: no adjustment; Child-Pugh class B: 50 mg once daily; Child-Pugh class C: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction).
Not established for patients <18 years; safety and efficacy not evaluated.
For pain (≥2 years): sublingual tablet 2-6 mcg/kg every 4-8 hours; IV/IM 2-6 mcg/kg every 4-6 hours. For opioid use disorder (≥16 years): induction 2-4 mg, then titration to 12-16 mg once daily; safety in <16 years not established.
No dose adjustment required based on age alone; consider renal function for dosing.
Initiate at lowest dose (e.g., sublingual 2 mg, transdermal 5 mcg/h) and titrate slowly due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment; monitor renal and hepatic function.
None
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of serious harm or death with concomitant use of benzodiazepines or CNS depressants; requirement for patient access to emergency medical services and monitoring; risk of addiction, abuse, and misuse; risk of accidental exposure.
Cardiomyopathy: left ventricular dysfunction, congestive heart failure, risk increased with concurrent anthracyclines. Infusion reactions: dyspnea, hypotension, angioedema. Pulmonary toxicity: interstitial lung disease, pneumonitis. Embryo-fetal toxicity: oligohydramnios, fetal renal impairment. Exacerbation of chemotherapy-induced neutropenia.
Respiratory depression: ceiling effect exists, but risk increases with non-opioid-tolerant use or coadministration of CNS depressants,Potentiation of respiratory depression by benzodiazepines and alcohol,Neonatal opioid withdrawal syndrome: avoid prolonged use during pregnancy unless necessary,Adrenal insufficiency: risk with prolonged use,Androgen deficiency: may occur with chronic use,Hypotension, especially in hypovolemic patients,Biliary tract spasm: may cause constriction of sphincter of Oddi,Risk of misuse, abuse, and diversion
Hypersensitivity to bryrelimab or any excipients. Severe uncontrolled hypertension. Clinically significant left ventricular ejection fraction (LVEF) reduction below 50% or below institutional lower limit of normal.
Hypersensitivity to buprenorphine or any component of the formulation,Significant respiratory depression in non-opioid-tolerant patients,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction (including paralytic ileus),Monoamine oxidase inhibitor (MAOI) use within past 14 days (relative contraindication; may precipitate serotonin syndrome),Mild to moderate hepatic impairment: use with caution; severe hepatic impairment: contraindicated
Avoid dairy products (milk, yogurt, cheese), calcium-fortified foods, and high-calcium mineral water within 2 hours of dosing. Do not take with iron-rich foods or supplements. Grapefruit juice may increase doxycycline absorption; avoid concurrent intake. Alcohol is not contraindicated but may increase GI upset.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition. Avoid excessive alcohol. Maintain a balanced diet to support overall health during treatment.
BRYREL (brivaracetam) is classified as FDA Pregnancy Category C. In animal studies, brivaracetam caused developmental toxicity (increased incidence of fetal malformations and embryofetal death) at maternal toxic doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure carries a potential risk of major congenital malformations, particularly neural tube defects and orofacial clefts, based on animal data and class effect of other antiepileptic drugs. Second and third trimester exposure may be associated with adverse neurodevelopmental outcomes. Use only if potential benefit justifies risk to fetus.
FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; may cause fetal respiratory depression if used near term.
Brivaracetam is excreted in human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.8. Limited data suggest infant serum levels are low, but systematic studies are lacking. Due to potential adverse effects in nursing infants (drowsiness, poor feeding), caution is advised. Manufacturer recommends discontinuing breastfeeding or the drug, considering the importance of the drug to the mother.
Buprenorphine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6 to 1.2. It is generally considered compatible with breastfeeding, but infants should be monitored for sedation and respiratory depression, especially in high maternal doses or with concomitant CNS depressants.
Pregnancy can decrease brivaracetam exposure due to increased clearance (by approximately 20-30% in the third trimester). Therapeutic drug monitoring is recommended, and dose adjustments may be necessary to maintain seizure control. Consider increasing the dose by 20-30% in the third trimester, with postpartum reduction to prepregnancy dose over 1-2 weeks to avoid toxicity. Individualize based on clinical response and trough concentrations.
No routine dose adjustment is recommended, but dose may need to be increased due to increased clearance and volume of distribution in pregnancy, particularly in the third trimester. Monitor for withdrawal symptoms (e.g., craving, anxiety, abdominal cramping) and consider incremental dose increases (by 2-4 mg) if needed. Postpartum, dose should be titrated back to prepregnancy level over 1-2 weeks.
BRYREL (doxycycline hyclate) is a tetracycline antibiotic with high oral bioavailability; administer with a full glass of water to reduce esophageal irritation. Avoid dairy products, antacids, iron, or bismuth subsalicylate within 2 hours of dosing due to chelation. Use sunscreen and protective clothing due to photosensitivity. Monitor for superinfection, especially candidiasis. In pediatric patients <8 years, contraindicated due to permanent tooth discoloration.
Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu receptors, which can precipitate withdrawal if given to opioid-dependent patients already on full agonists. Sublingual administration avoids first-pass metabolism. Monitor liver function due to hepatotoxicity risk, especially with injectable forms. Long half-life allows every-other-day dosing in maintenance therapy. Naloxone is added in combination products to deter intravenous abuse.
Take exactly as prescribed; complete the full course even if you feel better.,Swallow capsule whole with plenty of water; do not crush or chew.,Avoid milk, yogurt, cheese, antacids, iron supplements, or bismuth subsalicylate within 2 hours before or after taking BRYREL.,Avoid prolonged sun exposure; use sunscreen and protective clothing; report severe sunburn-like reactions.,If you miss a dose, take it as soon as you remember unless it's near the time of the next dose; do not double the dose.,Contact your healthcare provider if you develop watery or bloody diarrhea, severe headache, blurred vision, or signs of liver problems (dark urine, yellowing skin/eyes).,Do not use if you are pregnant, planning to become pregnant, or breastfeeding unless directed by your doctor.,Store at room temperature away from moisture and heat; keep out of reach of children.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not use alcohol, benzodiazepines, or other sedatives while on buprenorphine as it can cause severe drowsiness, respiratory depression, or coma.,Avoid driving or operating heavy machinery until you know how buprenorphine affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store safely out of reach of children; accidental ingestion can be fatal.,Inform your doctor if you have liver disease, breathing problems, or are pregnant.,If you miss a dose, take it as soon as possible; skip if almost time for next dose. Do not double dose.
No interactions on record
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRYREL vs BUPRENORPHINE, answered by our medical review team.
BRYREL is a Opioid Partial Agonist that works by BRYREL (bryrelimab) is a monoclonal antibody that binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting downstream signaling pathways including PI3K/Akt and MAPK, leading to cell cycle arrest and apoptosis in HER2-overexpressing tumor cells. It also mediates antibody-dependent cellular cytotoxicity (ADCC).. BUPRENORPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRYREL and BUPRENORPHINE depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRYREL is: 100 mg orally once daily, with or without food.. The standard adult dose of BUPRENORPHINE is: Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRYREL and BUPRENORPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRYREL is classified as Category C. BRYREL (brivaracetam) is classified as FDA Pregnancy Category C. In animal studies, brivaracetam caused developmental toxicity (increased incidence of fetal malformations and embry. BUPRENORPHINE is classified as Category C. FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal ano. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.